179 related articles for article (PubMed ID: 25933140)
1. Ipilimumab-Induced Granulomatous Disease Occurring Simultaneously With Disease Progression in a Patient With Metastatic Melanoma.
Toumeh A; Sakhi R; Shah S; Arudra SK; De Las Casas LE; Skeel RT
Am J Ther; 2016; 23(4):e1068-71. PubMed ID: 25933140
[TBL] [Abstract][Full Text] [Related]
2. Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma.
Quirk SK; Shure AK; Agrawal DK
Transl Res; 2015 Nov; 166(5):412-24. PubMed ID: 26118951
[TBL] [Abstract][Full Text] [Related]
3. Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade.
Sheik Ali S; Goddard AL; Luke JJ; Donahue H; Todd DJ; Werchniak A; Vleugels RA
JAMA Dermatol; 2015 Feb; 151(2):195-9. PubMed ID: 25321335
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma.
Yamazaki N; Kiyohara Y; Uhara H; Fukushima S; Uchi H; Shibagaki N; Tsutsumida A; Yoshikawa S; Okuyama R; Ito Y; Tokudome T
Cancer Chemother Pharmacol; 2015 Nov; 76(5):997-1004. PubMed ID: 26410424
[TBL] [Abstract][Full Text] [Related]
5. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network.
Voskens CJ; Goldinger SM; Loquai C; Robert C; Kaehler KC; Berking C; Bergmann T; Bockmeyer CL; Eigentler T; Fluck M; Garbe C; Gutzmer R; Grabbe S; Hauschild A; Hein R; Hundorfean G; Justich A; Keller U; Klein C; Mateus C; Mohr P; Paetzold S; Satzger I; Schadendorf D; Schlaeppi M; Schuler G; Schuler-Thurner B; Trefzer U; Ulrich J; Vaubel J; von Moos R; Weder P; Wilhelm T; Göppner D; Dummer R; Heinzerling LM
PLoS One; 2013; 8(1):e53745. PubMed ID: 23341990
[TBL] [Abstract][Full Text] [Related]
6. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
Graziani G; Tentori L; Navarra P
Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
[TBL] [Abstract][Full Text] [Related]
7. Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy.
Danielli R; Ridolfi R; Chiarion-Sileni V; Queirolo P; Testori A; Plummer R; Boitano M; Calabrò L; Rossi CD; Giacomo AM; Ferrucci PF; Ridolfi L; Altomonte M; Miracco C; Balestrazzi A; Maio M
Cancer Immunol Immunother; 2012 Jan; 61(1):41-8. PubMed ID: 21833591
[TBL] [Abstract][Full Text] [Related]
8. Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy.
Bronstein Y; Ng CS; Hwu P; Hwu WJ
AJR Am J Roentgenol; 2011 Dec; 197(6):W992-W1000. PubMed ID: 22109345
[TBL] [Abstract][Full Text] [Related]
9. Ipilimumab after progression on anti-PD-1 treatment in advanced melanoma.
Aya F; Gaba L; Victoria I; Fernández-Martínez A; Tosca M; Prat A; Arance A
Future Oncol; 2016 Dec; 12(23):2683-2688. PubMed ID: 27581765
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic T-lymphocyte antigen-4 blockade in melanoma.
Buchbinder EI; McDermott DF
Clin Ther; 2015 Apr; 37(4):755-63. PubMed ID: 25746738
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1.
Simeone E; Ascierto PA
J Immunotoxicol; 2012; 9(3):241-7. PubMed ID: 22524673
[TBL] [Abstract][Full Text] [Related]
12. Ipilimumab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash.
Nallapaneni NN; Mourya R; Bhatt VR; Malhotra S; Ganti AK; Tendulkar KK
J Natl Compr Canc Netw; 2014 Aug; 12(8):1077-81. PubMed ID: 25099440
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
[TBL] [Abstract][Full Text] [Related]
15. Management of immune-related adverse events and kinetics of response with ipilimumab.
Weber JS; Kähler KC; Hauschild A
J Clin Oncol; 2012 Jul; 30(21):2691-7. PubMed ID: 22614989
[TBL] [Abstract][Full Text] [Related]
16. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events.
Weber J
Oncologist; 2007 Jul; 12(7):864-72. PubMed ID: 17673617
[TBL] [Abstract][Full Text] [Related]
17. CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations.
Camacho LH
Cancer Med; 2015 May; 4(5):661-72. PubMed ID: 25619164
[TBL] [Abstract][Full Text] [Related]
18. A case report of orbital inflammatory syndrome secondary to ipilimumab.
Henderson AD; Thomas DA
Ophthalmic Plast Reconstr Surg; 2015; 31(3):e68-70. PubMed ID: 24814274
[TBL] [Abstract][Full Text] [Related]
19. Ipilimumab (Yervoy) and the TGN1412 catastrophe.
Bakacs T; Mehrishi JN; Moss RW
Immunobiology; 2012 Jun; 217(6):583-9. PubMed ID: 21821307
[TBL] [Abstract][Full Text] [Related]
20. New-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing CTLA4 monoclonal antibody treatment.
Murphy KP; Kennedy MP; Barry JE; O'Regan KN; Power DG
Oncol Res Treat; 2014; 37(6):351-3. PubMed ID: 24903767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]